Form 4: STAAR Surgical COO Warren Foust Reports Stock and Options Grant

Warren Foust, Chief Operating Officer of STAAR Surgical, reports the acquisition of restricted stock units and stock options.

Summary

• Warren Foust, the Chief Operating Officer of STAAR Surgical Co., filed a Form 4 on March 13, 2024, reporting transactions related to the company's securities.
• On March 12, 2024, Foust was granted 24,525 restricted stock units (RSUs) and 21,966 stock options.
• The RSUs will vest in three equal installments on March 12, 2025, March 12, 2026, and March 12, 2027.
• The stock options, with an exercise price of $37.64, will vest as to 1/3 on March 12, 2025, with the remaining 2/3 vesting monthly over the following 24 months, with any remaining balance vesting on March 12, 2027.
• Following these transactions, Foust directly owns 24,525 RSUs and 21,996 stock options.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. The sentiment is neutral to slightly positive.

Positives

• The grant of RSUs and stock options to the COO aligns his interests with those of the shareholders, incentivizing him to improve the company's performance.
• The vesting schedule encourages long-term commitment from the COO.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the vesting schedule of the RSUs and stock options suggests an expectation of continued service and contribution from the COO.

Industry Context

This type of equity grant is a common practice in publicly traded companies to incentivize and retain key executives. The vesting schedule is typical for such grants.

Comparison to Industry Standards

• Equity compensation for executives in the medical device industry, like STAAR Surgical, typically includes a mix of stock options and restricted stock units (RSUs).
• Vesting schedules of three to four years are standard to ensure long-term alignment with company performance.
• Companies like Alcon and Johnson & Johnson also utilize similar equity compensation structures for their executives.

Stakeholder Impact

• Shareholders may view the equity grants positively as they incentivize management to improve company performance.
• Employees may see the grants as a sign of the company's commitment to its leadership.

Key Dates